Unjustified Antipsychotic Use
Summary
The facility failed to ensure that two residents were free from antipsychotic medication use without an appropriate indication. For one resident, the electronic record documented diagnoses including insomnia, amnesia, hostility, anxiety disorder, chronic kidney disease, chronic anemia secondary to blood loss, and low back pain. The quarterly MDS showed intact cognition with no delirium, psychosis, or behaviors, yet the resident received an antipsychotic on a routine basis without a gradual dose reduction and without physician documentation that a GDR was clinically contraindicated. For that resident, the psychotropic drug use CAA was triggered because of psychotropic medication use and noted depression and ongoing psychotropic use. The care plan referenced a history of short-term memory issues and behaviors such as rejection of care and verbal aggression, and it directed staff to monitor for side effects and adverse reactions of antipsychotic and psychoactive medications. The physician order directed quetiapine 25 mg in the evening for hostility, but the pharmacy consultant note lacked a rationale for continued quetiapine use for the unapproved indication of hostility. The chart also lacked physician documentation of the rationale and risks versus benefits for quetiapine and lacked documentation of nonpharmacological interventions attempted and unsuccessful before the antipsychotic was started. Staff interviews described the resident as kind, helpful, and not exhibiting hostility or behaviors. For the second resident, the EMR documented dementia without behavioral disturbance and major depressive disorder. The annual MDS showed a BIMS score of 14, indicating intact cognition, and documented that the resident rejected care daily and received antipsychotic and antidepressant medication routinely. The care plan included interventions for behaviors such as agitation, inappropriate toileting, and sexually inappropriate comments, and the active order listed Zyprexa 2.5 mg in the evening for dementia without behavioral disturbances. The EMR lacked documentation of an appropriate indication and a risk-versus-benefit rationale for continued Zyprexa use, and an administrative nurse stated that the diagnosis of dementia was not approved by CMS and that the physician had not provided a different diagnosis or risk-versus-benefit documentation for the medication.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.